LifeSci Startup

Parse Biosciences, a leader in accessible and scalable single-cell sequencing solutions, welcomes OMAPiX as the newest member of its Certified Service Provider (CSP) Program. With this partnership, OMAPiX joins a distinguished network of service labs offering Parse’s scalable single cell technology to researchers worldwide. More: https://lnkd.in/g83ej575 #lifescience #biotech #healthcare

Biolojic Design, Ltd., a biotech company leveraging computational biology and AI to create programmable medicines, is joining Johnson & Johnson Innovation – JLABS in Washington, D.C., gaining access to lab space, resources, and collaboration opportunities as it establishes a U.S. presence. Learn more: https://lnkd.in/gDMUgpHU #lifescience #biotech #healthcare #medicine

Cellares, the pioneering Integrated Development and Manufacturing Organization (IDMO) for automated cell therapy, has appointed Ossama Eissa as Chief Operating Officer. Formerly with Novartis, Lonza Biologics, and Legend Biotech, Eissa joins Cellares at a pivotal time of rapid global expansion. Learn more: https://lnkd.in/gpVkiFBk #healthcare #lifescience #biotech #COO

Exciting developments from Adipo Therapeutics! At the recent Obesity Society annual meeting in San Antonio, Adipo presented promising data from two studies on ADPO-002, their active ingredient targeting obesity and metabolic disorders. The studies reveal how ADPO-002 stimulates key browning markers, supporting mitochondrial biogenesis and activation in human fat cells and tissues. These findings underscore ADPO-002’s potential to reshape the future of obesity treatment. More: https://lnkd.in/gDUE_u96 #ObesityResearch #healthcare #lifescience #health

VERAVAS, Inc., a leader in clinical diagnostics, is partnering with Phanes Biotech to co-develop a groundbreaking blood-based test for Alzheimer’s disease. This test will combine Veravas’ advanced VeraBIND™ technology with Phanes’ expertise in neurodegenerative diseases to detect #Alzheimers by studying interactions between specific tau proteins in the brain. Learn more: https://lnkd.in/gG9q3n_V #lifescience #biotech #healthcare #disease

Alimetry has raised an oversubscribed $18M A2 round to commercialize its #AI-powered gut health device, now adopted by a growing number of U.S. hospitals following its fourth #FDA clearance, a new CPT III reimbursement code, and over 30 clinical studies. Learn more: https://lnkd.in/gSU-CXn7 #healthcare #biotech #lifescience

Synaffix BV, a Lonza company, has licensed its clinical-stage ADC technology to BigHat Biosciences. This partnership will integrate Synaffix's platform with BigHat's machine-learning antibody design, creating a new ADC pipeline. BigHat gains access to late-stage, site-specific ADC technology and Lonza’s comprehensive DNA-to-IND services, streamlining the path to clinical trials. Learn More: https://lnkd.in/gM6bkjuU #biotech #lifescience #healthcare

Protein-design startup Archon Biosciences has secured $20M to advance its innovative antibody cages technology, which controls drug distribution in the body. Archon, which comes from the lab of Nobel Prize winner and University of Washington professor David Baker, aims to transform antibody-based therapies. Learn more: https://lnkd.in/gP6KQkgX #biotech #lifescience #innovation #bioscience

Werewolf Therapeutics expands its pipeline with WTX-921, a novel IL-10 INDUKINE candidate targeting IBD and other inflammatory diseases, showcasing the potential of its PREDATOR® platform beyond oncology. Learn more: https://lnkd.in/gDqD-bND #healthcare #lifescience #biotech #oncology

AbbVie is set to acquire Aliada Therapeutics, a brain-focused drugmaker backed by Johnson & Johnson, in a $1.4 billion deal. This acquisition will provide AbbVie with a clinical-stage Alzheimer’s treatment and innovative drug-making technology with potential applications across various brain diseases. Learn more: https://lnkd.in/grv5gUa6 #lifescience #biotech #alzheimers #healthcare